Praxis Precision Medicines Reports Positive Results of PRAX-628 Study Evaluating Photo Paroxysmal Response Achieving 100% Response in Treated Patients

Praxis Precision Medicines, Inc. provided an update on its Phase 2a proof of concept study evaluating PRAX-628 in epilepsy patients with PPR. PPR studies measure electroencephalogram signatures after...

Related Keywords

, Praxis Precision Medicines Inc , Praxis Precision Medicines , Response Assessment , Focal Epilepsy , Markets ,